



Original article

Use of the guidelines directed medical therapy after coronary artery bypass graft surgery in Saudi Arabia

Khalid A. Alburikan^{a,*}, Rakan I. Nazer^b^a College of Pharmacy, King Saud University, Riyadh, Saudi Arabia^b College of Medicine, King Saud University, Riyadh, Saudi Arabia

ARTICLE INFO

Article history:

Received 19 July 2016

Accepted 15 December 2016

Available online 26 December 2016

Keywords:

Guideline Directed Medical Therapy

(GDMT)

Coronary artery bypass grafting (CABG)

Secondary prevention

Pharmacotherapy

ABSTRACT

Background: incidence of cardiovascular diseases in Saudi Arabia is growing and more patients are expected to have cardiac revascularization surgery. Optimal pharmacotherapy management with Guideline Directed Medical Therapy (GDMT) post coronary artery bypass grafting (CABG) plays an important role in the prevention of adverse cardiovascular outcomes. The objective of this study was to assess the utilization of GDMT for secondary prevention in CABG patients and determine whether specific patients' characteristics can influence GDMT utilization. **Method:** A retrospective chart review of patients discharged from the hospital after CABG surgery from April 2015 to April 2016. The primary outcome was the utilization of secondary prevention GDMT after CABG surgery - aspirin, B-blockers, statin and angiotensin-converting enzyme inhibitors (ACEI) (or angiotensin receptor blockers (ARB) in ACEI-intolerant patients). The proportions of eligible and ideal patients who received treatment were calculated, and mixed-effects logistic regression was used to estimate odds ratios (OR) for the association of age, gender or patient nationality with the use of GDMT. **Results:** A total number of 119 patients included in the analysis. The median age of the cohort was 57.3 ± 11 years, and 83% were male (83.2%). Nearly 69.7% of patients had diabetes, and 82% had a previous diagnosis of hypertension. Nearly 91% received aspirin therapy and the rate was lower for B-blocker and statin. The rate of GDMT utilization did not change with the change in patient's age, gender or nationality. **Conclusion:** Despite adjustments for contraindications to GDMT, the rate of GDMT utilization was suboptimal.

© 2016 The Authors. Production and hosting by Elsevier B.V. on behalf of King Saud University. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

1. Introduction

Coronary artery bypass grafting (CABG) is a recognized surgical procedure that improves survival in patients with significant left main coronary artery stenosis (>70% diameter) and in patients with multiple vessel disease (Hillis et al., 2012). Nearly, 400,000 patient undergo coronary artery revascularization surgeries each year in the United States (Heart Disease and Stroke Statistics, 2016; Hillis et al., 2012). Our center annually performs close to 400 open-heart procedures a year. Isolated CABG makes 50% of the

caseload, CABG combined with other valve procedures 15%, valve repairs/replacements 30%, and 5% for other procedures such as aortic dissection and adult congenital.

However, coronary artery revascularization surgery restores the oxygen supply and the blood flow to the myocardium tissues as a result of bypassing the occluded arteries, and patients who have undergone CABG remain at risk for subsequent cardiovascular ischemic events. (Smith et al., 2011) Subsequent ischemic events can result from native coronary artery disease (CAD) progression and the development of vein graft atherosclerosis (Farooq et al., 2012; Smith et al., 2011). Thus, international guidelines recommend guideline directed medical therapy (GDMT) as the mainstay of pharmacological therapy for CABG patients to improve survival and reduce subsequent cardiovascular events in the absence of any contraindications or intolerance (Kolh et al., 2014; Kulik et al., 2015). GDMT for CABG patients includes antiplatelet therapy, high-intensity statin, beta-blockers (BB) and angiotensin-converting enzyme inhibitors (ACEI) (or angiotensin receptor blockers (ARB) in ACEI-intolerant patients) (Kolh et al., 2014; Kulik et al., 2015). Secondary prevention with GDMT plays a key

* Corresponding author at: College of Pharmacy, King Saud University, P.O. Box 2475, Riyadh 11451, Saudi Arabia. Fax: +966 11 4678847.

E-mail address: kalburikan@ksu.edu.sa (K.A. Alburikan).

Peer review under responsibility of King Saud University.



Production and hosting by Elsevier

role in the maintenance of native and graft vessel patency and in the prevention of adverse cardiovascular outcomes (The MACB Study Group, 1995; Knatterud et al., 2000; Oosterga et al., 2001; Mangano et al., 2002; Warnica et al., 2002). Studies reported 69% improvement in 2-year survival in patients taking half or more of indicated GDMT following discharge compared to patients taking 50% or less half of indicated GDMT in CABG patients (Post Coronary Artery Bypass Graft Trial Investigators, 1997; Goyal et al., 2007; Kulik et al., 2015).

Despite the strong evidence for secondary prevention in CABG patients, many studies have reported suboptimal use of GDMT following CABG (Bi et al., 2009; Goyal et al., 2007). In the United States, the use of antiplatelet agents and statins was high at discharge and at 1 year, but the use of beta-blockers and ACEi or ARBs was suboptimal (Goyal et al., 2007). In China, the utilization GDMT was reported (above 90% for aspirin, 70% for beta-blockers and ACEi, and 80% for statin) at the time of hospital discharge but decreased during follow-up (Bi et al., 2009). Despite the high incidence of CAD, and subsequent mortality and morbidity in Saudi Arabia, the utilization of GDMT after CABG for secondary prevention is unknown (Al-Nozha et al., 2004).

The aim of this study was to evaluate the utilization of GDMT for secondary prevention in CABG patients in Saudi Arabia. Furthermore, it will determine the association between patients' demographic data such as age, gender and nationality and the use of GDMT to provide clinicians with evidence to better guide management of CABG patients.

2. Method

2.1. Study population

After ethical approval from the office of institutional review board, we screened all patients discharged from the hospital after CABG surgery from April 2015 to April 2016. We excluded patients with any conditions in which the GDMT after CABG is contraindicated (due to complications from surgery or extended length of stay at the intensive care unit >9 days), or they had any missing data.

2.2. Outcome and data collection

In this study, data from the medical reports of the eligible patients were reviewed. The primary outcome was the utilization of secondary prevention GDMT after CABG surgery. We reviewed discharge prescriptions for each patient included in the study. GDMT was defined based on 2015 American Heart Association (AHA) secondary prevention after CABG guidelines published in 10 March 2015 and includes the following (Kulik et al., 2015):

- Aspirin for all patients unless they are intolerant of or allergic to aspirin.
- B-Blockers for all patients unless they have of the following bradycardia or severe reactive airway disease.
- High-intensity statin therapy for all patients unless contraindicated.
- ACEi or ARBs for patients with one or more of the following conditions: left ventricular ejection fraction < 40%, Diabetes Mellitus (DM), recent myocardial infarction, and/or chronic kidney disease unless the patients have hypotension, hyperkalemia, and worsening renal function.

The following data were reviewed in each patient's medical report and the following data were collected including demographic information and past medical history (e.g., hypertension,

diabetes mellitus, chronic kidney disease, left ventricle dysfunction and myocardial infarction). Date of the CABG surgery and discharge medications prescribed after CABG (e.g., Antiplatelet drug, statins, B-blockers ACEi and others) were also collected.

2.3. Analytical methods

We used descriptive statistics to describe demographic and clinical characteristics of the patients. Percentages and frequencies were used for the categorical variables, while means and standard deviations were calculated for the continuous variables. We used mixed-effects logistic regression to estimate odds ratios (OR) for the association of age, gender or patient nationality with the use of GDMT. The SPSS (version 22.0; SPSS Inc., Chicago, Illinois) was used for all analyses.

3. Results

Of the 184 patients screened for the study, 119 (64%) patients met the inclusion criteria and included in the final assessment, and 65 patients were excluded (60% complications including prolonged intubation, infections and bleeding, 20% extended duration of stay and 20% different surgical procedures). The average age of the patients was 57.3 ± 11 years, most patients were male (83.2%) and the mean length of stay after the surgery was 9 days (Table 1). Approximately 69.7% of patients had diabetes, and nearly 82% had a previous diagnosis of hypertension. All patients included in the final assessment were eligible to receive aspirin, BB and statin after the surgery. Nearly 85% of the patients were eligible to receive ACE inhibitor or ARBs. At hospital discharge, rates of secondary prevention GDMT for use for candidate patients were suboptimal. The use of aspirin was 91%, β -blockers use was 81%, and

Table 1
Characteristics of discharges of patients following heart revascularization surgery.

Characteristics	(n = 119)
Age-Years	57.3 (11)
Female Gender	20 (16.8)
<i>Nationality</i>	
Saudi	48 (40.3%)
Non-Saudi	70 (59.6%)
Body Mass Index (kg/m ²)	27.4 (3)
<i>Comorbidities:</i>	
Diabetes	83 (69.7%)
Hypertension	98 (82.4%)
Hyperlipidemia	89 (74.8)
Atrial Fibrillation	24 (20%)
Prior Myocardial Infarction	19 (16%)
Left Ventricular Ejection Fraction < 40%	23 (19%)
Chronic Obstructive Pulmonary Disease	12 (10.1%)
Tobacco Use	36 (30.3%)
Chronic Kidney Disease	36 (30.3%)
<i>Exam/Laboratory Values^a</i>	
Blood Pressure (mmHg)	132 (28)
Heart Rate (bpm)	84 (18)
BUN (mg/dL)	23 (16)
Creatinine Clearance (mL/min)	82.8 (29.2)
Sodium (mEq/L)	138 (5)
Potassium (mEq/L)	4.1 (0.5)
Alanine Aminotransferase-ALT (U/L)	47.2 (23.5)
Aspartate Aminotransferase-AST (U/L)	34.7 (25.3)
<i>Miscellaneous</i>	
Post-op Stay – Days	8 (6)
Intensive Care Time-Hours	44.3 (31.5)

Continuous variables are reported as mean (SD), and constant variables are reported as number (percentage).

^a Value reported at the day of discharge, or lowest value after the cardiac revascularization surgery.

Download English Version:

<https://daneshyari.com/en/article/5551429>

Download Persian Version:

<https://daneshyari.com/article/5551429>

[Daneshyari.com](https://daneshyari.com)